These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35580151)

  • 21. Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
    FitzGerald R; Dickinson L; Else L; Fletcher T; Hale C; Amara A; Walker L; Penchala SD; Lyon R; Shaw V; Greenhalf W; Bullock K; Lavelle-Langham L; Reynolds H; Painter W; Holman W; Ewings S; Griffiths G; Khoo S
    Clin Infect Dis; 2022 Aug; 75(1):e525-e528. PubMed ID: 35271729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nudix hydrolase 18 catalyzes the hydrolysis of active triphosphate metabolites of the antivirals remdesivir, ribavirin, and molnupiravir.
    Jemth AS; Scaletti ER; Homan E; Stenmark P; Helleday T; Michel M
    J Biol Chem; 2022 Aug; 298(8):102169. PubMed ID: 35732208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What impact can molnupiravir have on the treatment of SARS-CoV-2 infection?
    Kayali F; Leung MST; Wong W; Morgan KP; Harky A
    Expert Opin Pharmacother; 2022 Jun; 23(8):865-868. PubMed ID: 35341442
    [No Abstract]   [Full Text] [Related]  

  • 24. Molnupiravir inhibits human norovirus and rotavirus replication in 3D human intestinal enteroids.
    Santos-Ferreira N; Van Dycke J; Chiu W; Neyts J; Matthijnssens J; Rocha-Pereira J
    Antiviral Res; 2024 Mar; 223():105839. PubMed ID: 38373532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The COVID-19 Oral Drug Molnupiravir Is a CES2 Substrate: Potential Drug-Drug Interactions and Impact of CES2 Genetic Polymorphism In Vitro.
    Shen Y; Eades W; Liu W; Yan B
    Drug Metab Dispos; 2022 Sep; 50(9):1151-1160. PubMed ID: 35790245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decoding molnupiravir-induced mutagenesis in SARS-CoV-2.
    Menéndez-Arias L
    J Biol Chem; 2021 Jul; 297(1):100867. PubMed ID: 34118236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Virology and safety profile of Molnupiravir at three different doses for treatment of SARS-CoV-2: a systematic review and meta-analysis.
    Sukaina M; Shuja SH; Rehan ST; Ochani S; Sheryar M
    APMIS; 2024 Mar; 132(3):139-151. PubMed ID: 38288881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2022 Feb; 16(2):102396. PubMed ID: 35051686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity against Enterovirus Infections In Vitro and In Vivo.
    Li Y; Liu M; Yan Y; Wang Z; Dai Q; Yang X; Guo X; Li W; Chen X; Cao R; Zhong W
    Viruses; 2022 May; 14(6):. PubMed ID: 35746614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molnupiravir; molecular and functional descriptors of mitochondrial safety.
    Wallace KB; Bjork JA
    Toxicol Appl Pharmacol; 2022 May; 442():116003. PubMed ID: 35358570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molnupiravir in COVID-19: A Scoping Review.
    Kaore S; Atal S
    Curr Drug Res Rev; 2022; 14(3):203-214. PubMed ID: 35638286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients.
    Parums DV
    Med Sci Monit; 2022 Jan; 28():e935952. PubMed ID: 34972812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Highly sensitive high-performance thin-layer chromatography method for the simultaneous determination of molnupiravir, favipiravir, and ritonavir in pure forms and pharmaceutical formulations.
    Saraya RE; Deeb SE; Salman BI; Ibrahim AE
    J Sep Sci; 2022 Jul; 45(14):2582-2590. PubMed ID: 35583051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model.
    Lieber CM; Cox RM; Sourimant J; Wolf JD; Juergens K; Phung Q; Saindane MT; Smith MK; Sticher ZM; Kalykhalov AA; Natchus MG; Painter GR; Sakamoto K; Greninger AL; Plemper RK
    Nat Commun; 2022 Jul; 13(1):4416. PubMed ID: 35906230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel property of hexokinase inhibition by Favipiravir and proposed advantages over Molnupiravir and 2 Deoxy D glucose in treating COVID-19.
    Kulkarni P; Padmanabhan S
    Biotechnol Lett; 2022 Jul; 44(7):831-843. PubMed ID: 35608787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template.
    Gordon CJ; Tchesnokov EP; Schinazi RF; Götte M
    J Biol Chem; 2021 Jul; 297(1):100770. PubMed ID: 33989635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two short approaches to the COVID-19 drug β-D-
    Persaud KE; Sahu RR; Neary MC; Kapdi AR; Lakshman MK
    Org Biomol Chem; 2024 Jan; 22(4):735-740. PubMed ID: 38168802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir.
    Parums DV
    Med Sci Monit; 2022 Oct; 28():e938532. PubMed ID: 36181334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Engineered Cytidine Deaminase for Biocatalytic Production of a Key Intermediate of the Covid-19 Antiviral Molnupiravir.
    Burke AJ; Birmingham WR; Zhuo Y; Thorpe TW; Zucoloto da Costa B; Crawshaw R; Rowles I; Finnigan JD; Young C; Holgate GM; Muldowney MP; Charnock SJ; Lovelock SL; Turner NJ; Green AP
    J Am Chem Soc; 2022 Mar; 144(9):3761-3765. PubMed ID: 35224970
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molnupiravir: From Hope to Epic Fail?
    Focosi D
    Viruses; 2022 Nov; 14(11):. PubMed ID: 36423169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.